Dendritic Cells and Live Tumor Cells in Cancer Immunotherapy
Author Information
Author(s): Matheoud Diana, Baey Camille, Vimeux Lene, Tempez Andy, Valente Michael, Louche Pauline, Le Bon Agnès, Hosmalin Anne, Feuillet Vincent
Primary Institution: Inserm, U1016, Institut Cochin, Paris, France
Hypothesis
Can dendritic cells cross-present antigens from live tumor cells more effectively than from apoptotic cells?
Conclusion
Dendritic cells cross-presenting antigens from live B16 melanoma cells induce stronger anti-tumor responses than those from apoptotic cells.
Supporting Evidence
- Live B16 cells induced a significantly lower number of tumors in treated mice compared to those treated with apoptotic cells.
- DC cultured with live cells produced stronger CD8+ T-cell responses.
- Live cells maintained antigens in a more native form, enhancing cross-presentation efficiency.
Takeaway
This study shows that using live tumor cells can help immune cells better recognize and fight cancer.
Methodology
Mice were injected with B16 melanoma cells and treated with dendritic cells cultured with either live or apoptotic cells to assess tumor protection and immune response.
Limitations
The study was conducted in mice, which may not fully replicate human responses.
Participant Demographics
C57Bl/6 mice, aged 8-12 weeks.
Statistical Information
P-Value
0.0029
Statistical Significance
p=0.0029
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website